» Articles » PMID: 38443946

Pancancer Analysis of the Prognostic and Immunological Role of FANCD2: a Potential Target for Carcinogenesis and Survival

Overview
Publisher Biomed Central
Specialty Genetics
Date 2024 Mar 5
PMID 38443946
Authors
Affiliations
Soon will be listed here.
Abstract

Recent evidence has shed light on the significant role of FANCD2 in cancer initiation, development, and progression. However, a comprehensive pan-cancer analysis of FANCD2 has been lacking. In this study, we have conducted a thorough investigation into the expression profiles and prognostic significance of FANCD2, as well as its correlation with clinicopathological parameters and immune cell infiltration, using advanced bioinformatic techniques. The results demonstrate that FANCD2 is significantly upregulated in various common cancers and is associated with prognosis. Notably, higher expression levels of FANCD2 are linked to poor overall survival, as indicated by Cox regression and Kaplan-Meier analyses. Additionally, we have observed a decrease in the methylation of FANCD2 DNA in some cancers, and this decrease is inversely correlated with FANCD2 expression. Genetic alterations in FANCD2 predominantly manifest as mutations, which are associated with overall survival, disease-specific survival, disease-free survival, and progression-free survival in certain tumor types. Moreover, FANCD2 exhibits a strong correlation with infiltrating cell levels, immune checkpoint genes, tumor mutation burden (TMB), and microsatellite instability (MSI). Enrichment analysis further highlights the potential impact of FANCD2 on Fanconi anemia (FA) pathway and cell cycle regulation. Through this comprehensive pan-cancer analysis, we have gained a deeper understanding of the functions of FANCD2 in oncogenesis and metastasis across different types of cancer.

Citing Articles

Pancreatic Neuroendocrine Tumor: The Case Report of a Patient with Germline Mutation and Tumor Analysis Using Single-Cell RNA Sequencing.

Avsievich E, Salimgereeva D, Maluchenko A, Antysheva Z, Voloshin M, Feidorov I J Clin Med. 2025; 13(24.

PMID: 39768544 PMC: 11728285. DOI: 10.3390/jcm13247621.


Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case-Control Study.

Alanazi N, Siyal A, Basit S, Shammas M, Al-Mukhaylid S, Aleem A Hematol Rep. 2024; 16(3):465-478.

PMID: 39051418 PMC: 11270283. DOI: 10.3390/hematolrep16030045.


RNA-binding protein transcripts as potential biomarkers for detecting Primary Sclerosing Cholangitis and for predicting its progression to Cholangiocarcinoma.

Ala U, Fagoonee S Front Mol Biosci. 2024; 11:1388294.

PMID: 38903178 PMC: 11187294. DOI: 10.3389/fmolb.2024.1388294.


Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship.

Nicu A, Ionel I, Stoica I, Burlibasa L, Jinga V Biomedicines. 2024; 12(5).

PMID: 38791003 PMC: 11117643. DOI: 10.3390/biomedicines12051041.

References
1.
Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

2.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

3.
Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L . Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050. JAMA Oncol. 2023; 9(4):465-472. PMC: 9951101. DOI: 10.1001/jamaoncol.2022.7826. View

4.
Carrera P, Kantarjian H, Blinder V . The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018; 68(2):153-165. PMC: 6652174. DOI: 10.3322/caac.21443. View

5.
Lin L, Li Z, Yan L, Liu Y, Yang H, Li H . Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019. J Hematol Oncol. 2021; 14(1):197. PMC: 8607714. DOI: 10.1186/s13045-021-01213-z. View